STOCK TITAN

Ernexa Therapeutics (ERNA) Financials

ERNA NASDAQ
Trailing 12 months to September 30, 2026
Net Income -$14.0M YoY not available
EPS (Diluted) -$2.24 FY2025 annual
Free Cash Flow -$10.8M YoY not available
Operating Cash Flow -$10.7M n/m YoY
Market Cap $2.7M as of Nov 18, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.6x on $4.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ERNA SEC filings page.

This page shows Ernexa Therapeutics Inc. (ERNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ERNA FY2025

Ernexa's reported economics are dominated by development spending and financing, not by product revenue or internally funded operations.

Operating cash outflow narrowed from $15.8M in FY2024 to $7.0M in FY2025 as SG&A fell 60.7% and R&D fell 9.7%; however, the FY2025 net loss of $14.1M still exceeded cash outflow, showing that reduced spending—not operating revenue—drove the cash improvement.

The balance sheet became less burdened by liabilities in FY2025: liabilities fell 3.8% to $3.4M while equity rose 41.2% to $2.4M. Yet the 1.0x current ratio indicates current assets and current liabilities were approximately matched, leaving little short-term balance-sheet slack.

FY2025 financing provided $7.2M while operating activities used $7.0M and free cash flow was negative $7.1M. That combination means external financing effectively funded the year's cash needs, while the reported business still lacked revenue in the latest period.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Ernexa Therapeutics Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
3/5

Ernexa Therapeutics Inc. passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

Ernexa Therapeutics Inc. reported a net loss of $14.1M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Ernexa Therapeutics Inc. reported an operating loss of $9.3M against $22K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$3.0M
YoYn/m
QoQn/m

Ernexa Therapeutics Inc.'s EBITDA was -$3.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$2.9M
YoYn/m
QoQn/m

Ernexa Therapeutics Inc. reported a net loss of $2.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.89
QoQn/m

Ernexa Therapeutics Inc. earned -$1.89 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$3.2M
QoQn/m

Ernexa Therapeutics Inc. recorded an outflow of $3.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$5.6M
YoY+83.0%
QoQ+10.9%
5Y CAGR-25.6%
10Y CAGR+6.3%

Ernexa Therapeutics Inc. held $5.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
2M
QoQ+3.7%

Ernexa Therapeutics Inc. had 2M shares outstanding in Q3 2026. Against the prior quarter it is up 3.7%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-67.6%
YoY-32.9pp
QoQ+57.7pp

Ernexa Therapeutics Inc.'s quarterly ROE was -67.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 32.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 57.7 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$1.9M
YoY+80.8%
QoQ-33.0%
5Y CAGR+4.6%

Ernexa Therapeutics Inc. invested $1.9M in research and development in Q3 2026. This represents an increase of 80.8% from the same quarter a year earlier. Against the prior quarter it is down 33.0%.

Capital Expenditures
$0
QoQ-100.0%

Ernexa Therapeutics Inc. reported no capital expenditure in Q3 2026. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

ERNA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ERNA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
RevenueN/AN/AN/AN/AN/AN/AN/A$1K
Cost of Revenue$0n/m$0n/mN/AN/A$0n/m$0-100.0%N/A$0
Gross ProfitN/AN/AN/AN/AN/AN/AN/A$1K
R&D Expenses$1.9M+80.8%$2.8M+145.8%$1.9M+46.3%$676K-41.6%$1.0M+3.4%$1.1M+15.1%$1.3M-10.2%$1.2M-14.9%
SG&A Expenses$1.1M+16.8%$1.3M-3.9%$1.6M+14.8%$1.4M-7.9%$958K-71.7%$1.4M-65.0%$1.4M-67.1%$1.5M-64.6%
Operating Income-$3.0Mn/m-$4.1Mn/m-$5.6Mn/m-$2.1Mn/m-$2.0Mn/m-$2.5Mn/m-$2.7Mn/m-$2.7Mn/m
EBITDA-$3.0Mn/m-$4.1Mn/m-$5.6Mn/m-$2.1Mn/m-$2.0Mn/m-$2.5Mn/m-$2.7Mn/m-$2.7Mn/m
Interest ExpenseN/AN/AN/AN/AN/AN/A$6K-98.5%-$2.7M
Income TaxN/AN/A-$40K-600.0%-$62K-663.6%$6K-50.0%$3K0.0%$8K+100.0%$11Kn/m
Net Income-$2.9Mn/m-$4.0Mn/m-$5.5Mn/m-$1.5M-$1.2Mn/m-$3.1Mn/m-$8.2Mn/mN/A
EPS (Basic)-$1.89-$3.40-$6.95N/A-$3.77-$15.19-$57.76N/A
EPS (Diluted)-$1.89-$3.40-$6.95N/A-$3.77-$15.19-$57.76N/A
Diluted Shares (Avg)2M1M792,000N/A329,000207,000142,000N/A

ERNA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ERNA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$7.1M+15.1%$6.3M-16.7%$10.5M+108.4%$5.8M+10.7%$6.2M-20.0%$7.6M-83.7%$5.1M-89.8%$5.3M-89.3%
Current Assets$6.7M+99.1%$5.9M+23.0%$10.0M+352.1%$3.1M+33.2%$3.4M-28.6%$4.8M+33.7%$2.2M-64.1%$2.4M-75.5%
Cash & Equivalents$5.6M+83.0%$5.0M+16.5%$9.2M+378.5%$1.9M+9.0%$3.0M-28.5%$4.3M+66.9%$1.9M-62.5%$1.7M-77.2%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
GoodwillN/AN/AN/A$2.0M0.0%$2.0M0.0%$2.0M0.0%$2.0M0.0%$2.0M0.0%
Total Liabilities$2.8M+5.8%$3.1M-0.8%$3.7M-66.5%$3.4M-3.8%$2.6M-95.1%$3.1M-94.3%$11.0M-79.3%$3.6M-92.4%
Current Liabilities$2.6M+21.9%$2.9M+10.6%$3.5M-66.9%$3.1M+6.0%$2.1M-78.5%$2.7M-72.4%$10.4M+34.4%$2.9M-55.3%
Non-Current Liabilities$139K-69.7%$183K-62.6%$227K-60.2%$320K-49.2%$458K-98.9%$489K-98.9%$571K-98.7%$630K-98.4%
Total Equity$4.4M+21.9%$3.2M-28.0%$6.9Mn/m$2.4M+41.2%$3.6Mn/m$4.4Mn/m-$6.0Mn/m$1.7M-23.8%
Retained Earnings-$258.1Mn/m-$255.2Mn/m-$251.1Mn/m-$245.6Mn/m-$244.1Mn/m-$242.9Mn/m-$239.7Mn/m-$231.5Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.

ERNA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ERNA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$3.2Mn/m-$4.2Mn/m-$2.3Mn/m-$1.1Mn/m-$1.3Mn/m-$2.5Mn/m-$2.1Mn/m-$3.5Mn/m
Depreciation & Amortization$10K-41.2%$9K-47.1%$8K-55.6%$13K-31.6%$17K-54.1%$17K-61.4%$18K-53.8%$19K-13.6%
Stock-Based Compensation$377K+28.7%$320K-13.0%$309K-38.4%N/A$293K-27.7%$368K-13.0%$502K+78.0%N/A
Capital Expenditures$0$3K$2K$15Kn/mN/AN/AN/A$0-100.0%
Free Cash Flow-$3.2M-$4.2M-$2.3M-$1.2Mn/mN/AN/AN/A-$3.5Mn/m
Investing Cash Flow$0-$3K-$2K-$15Kn/mN/AN/AN/A$0n/m
Financing Cash Flow$3.7M+14196.2%$6K-99.9%$9.6M+324.1%$0-100.0%$26K-99.3%$4.9Mn/m$2.3M+62.7%$1.0M-86.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ERNA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ERNA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross MarginN/AN/AN/AN/AN/AN/AN/A100.0%
Operating MarginN/AN/AN/AN/AN/AN/AN/A-269700.0%
Return on Equity-67.6%-32.9pp-125.3%-54.6pp-80.3%-62.6%-34.7%-70.7%N/AN/A
Return on Assets-41.4%-21.3pp-63.5%-22.1pp-52.2%+109.9pp-25.8%-20.1%+324.6pp-41.4%-29.5pp-162.1%-148.7ppN/A
Current Ratio2.57+1.0x2.01+0.2x2.89+2.7x1.01+0.2x1.58+1.1x1.81+1.4x0.21-0.6x0.80-0.7x
Liabilities-to-Equity0.63-0.1x0.97+0.3x0.541.43-0.7x0.730.71N/A2.10-18.9x
Asset TurnoverN/AN/AN/AN/AN/AN/AN/A0.00
FCF MarginN/AN/AN/AN/AN/AN/AN/A-354500.0%

Not reported in any period shown, so not listed: Net Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Ernexa Therapeutics Inc. ERNA FY2025 N/A -$14.1M N/A $2.7M —
Mustang Bio, Inc. MBIO FY2025 N/A -$1.9M N/A $2.9M —
Curis Inc CRIS FY2025 $9.4M -$7.6M -80.3% $5.8M 43/100
Purple Biotech Ltd. PPBT FY2025 N/A N/A N/A $2.8M —
Calidi Biotherapeutics, Inc. CLDI FY2025 N/A -$19.9M N/A $1.8M —
NeuroSense Therapeutics Ltd. NRSN FY2025 N/A N/A N/A $2.6M —

Frequently Asked Questions

No, Ernexa Therapeutics Inc. (ERNA) reported a net loss of $14.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $14.1M.

Ernexa Therapeutics Inc. (ERNA) reported diluted earnings per share of -$2.24 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ernexa Therapeutics Inc. (ERNA) had EBITDA of -$9.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Ernexa Therapeutics Inc. (ERNA) has a return on equity of -586.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Ernexa Therapeutics Inc. (ERNA) recorded an outflow of $7.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Ernexa Therapeutics Inc. (ERNA) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Ernexa Therapeutics Inc. (ERNA) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Ernexa Therapeutics Inc. (ERNA) invested $37K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Ernexa Therapeutics Inc. (ERNA) invested $4.2M in research and development during fiscal year 2025.

Ernexa Therapeutics Inc. (ERNA) had 29M shares outstanding as of fiscal year 2025.

Ernexa Therapeutics Inc. (ERNA) had a current ratio of 1.01 as of fiscal year 2025, which is considered adequate.

Ernexa Therapeutics Inc. (ERNA) had a liabilities-to-equity ratio of 1.43 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Ernexa Therapeutics Inc. (ERNA) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Ernexa Therapeutics Inc. (ERNA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $2.7M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Ernexa Therapeutics Inc. (ERNA) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $2.7M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Ernexa Therapeutics Inc. (ERNA) held $1.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Ernexa Therapeutics Inc. (ERNA) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ernexa Therapeutics Inc. (ERNA) reported a net loss of $14.1M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Ernexa Therapeutics Inc. (ERNA) reported an operating loss of $9.3M against $22K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top